Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma

Clinical Trial ID NCT01545427

Rank	Title	Journal	Year	PubWeight™‹?›
1	Measurement of patient outcome in arthritis.	Arthritis Rheum	1980	21.31
2	Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.	J Rheumatol	1988	16.45
3	Regulation of PDGF and its receptors in fibrotic diseases.	Cytokine Growth Factor Rev	2004	3.14
4	Imatinib for the treatment of pulmonary arterial hypertension.	N Engl J Med	2005	2.69
5	A proposal of criteria for the classification of systemic sclerosis.	Med Sci Monit	2004	1.31
6	Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis.	J Rheumatol	2002	0.87
7	How to develop a successful cancer drug--molecules to medicines or targets to treatments?	Eur J Cancer	2005	0.85
8	Transforming growth factor-β1 in plaque morphea.	Postepy Dermatol Alergol	2013	0.83
9	Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth.	Digestion	2005	0.82
10	Current perspectives on the immunopathogenesis of systemic sclerosis.	Immunotargets Ther	2016	0.79
11	Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.	Rheumatology (Oxford)	2014	0.77
12	[Systemic sclerosis. A rare connective tissue disease with manifestations in many organs].	Tidsskr Nor Laegeforen	1995	0.75